Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

(2015) M. Ikeda et al.   CLINICAL CANCER RESEARCH

Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

(2015) Calin Cainap et al.   JOURNAL OF CLINICAL ONCOLOGY

A validated LC–MS/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis

(2015) Yuji Mano et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design

(2014) J. M. Llovet et al.   CLINICAL CANCER RESEARCH

Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration

(2014) Robert Shumaker et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan

(2014) Haruhiko Takeda et al.   LIVER INTERNATIONAL

Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies

(2014) Gaetano Bertino et al.   Biomed Research International

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

(2013) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

(2013) Ann-Lii Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

(2012) D S Boss et al.   BRITISH JOURNAL OF CANCER

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

(2011) Julien Edeline et al.   CANCER

Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma

(2011) Sadahisa Ogasawara et al.   Hepatology International

Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma

(2011) Peng Li   WORLD JOURNAL OF GASTROENTEROLOGY

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

(2008) J. Matsui et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   JNCI-Journal of the National Cancer Institute

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE